Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03163862
Other study ID # 0001
Secondary ID
Status Not yet recruiting
Phase Phase 2/Phase 3
First received May 21, 2017
Last updated June 16, 2017
Start date August 1, 2017
Est. completion date January 1, 2019

Study information

Verified date June 2017
Source Istishari Arab Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a controlled preminary trial intended to increase the implantation rate of IVF cycles, by using more than one known procedure, endometrial scratching, evaluating the status of the adhesive factors as αVβ3 integrin, L-selectin ligand MECA-79, E-cadherin and ICAM-1, as a determinant for intervention by G-CSF, according to a score that can be done on a small sample obtained during scratching, then give G-CSF for the scores less than 4 intrauterine and subcutaneously.


Description:

Placebo: CONTROL patients treated with PLACEBO (saline solution) from the day of embryo transfer through the day of beta hCG test Drug& scratching CONTROL saline infusion every day from the day of embryo transfer through the day of beta HCG test Other Name: SALINE INFUSION Experimental: G-CSF group patients treated with G-CSF if the biopsy adhesive score 1-3 only

1. Endometrial scratching and adhesive factor score, day 21-24 cycle prior to IVF//0rv day 3 of IVF cycle not planned before.

2. Drug &scratching : G-CSF group

1- 300 µg trans cervical intrauterine of G-CSF was administered at the oocyte retrieval day, 2- subcutaneous 300 micrograms G-CSF on the day of embryo transfer Comparative group patients not treated with G-CSF after scratching if the biopsy adhesive score 4 only

Scratching only :

Patients undergoing scratching on day 21-24 of prior IVF cycle/ and on day 5 of IVF cycle with biopsy score of 4.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date January 1, 2019
Est. primary completion date June 1, 2018
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 40 Years
Eligibility Inclusion Criteria:

- ALL Women aged < 40 years who would be submitted to oocyte retrieval and embryo transfer IN IVF cycle.

Exclusion Criteria:

- • contraindications for G-CSF treatment (sickle cell disease, chronic neutropenia, known past or present malignancy, renal insufficiency, upper respiratory infection, pneumonia, and congenital fructose intolerance)

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Endometrial scratch
the intervention group, endometrial biopsy will be performed with a pipelle de Cornier® (Laboratoires Prodimed, Neully-En-Thelle, France). The pipelle was introduced gently through the cervix up to the uterine fundus. the examiner applied regular back-and-forth movements (2-4 cm) during a period of 30 s. The obtained specimens will be sent for histology evaluation.
Drug:
G-CSF administration
1- 300 µg trans cervical intrauterine of G-CSF was administered at the oocyte retrieval day, subcutaneous 300 micrograms G-CSF on the day of embryo transfer
Saline Solution
saline infusion every day from the day of embryo transfer through the day of beta HCG test

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Istishari Arab Hospital Nizam Najeeb, Salem Abu Khyzaran

Outcome

Type Measure Description Time frame Safety issue
Primary clinical pregnancy per women randomized pregnancy diagnosed by ultrasonographic visualisation of one or more gestational sacs, including ectopic pregnancy 4 weeks
Secondary setting a score of precepative endometrium Evaluation of the endometrial biopsy and setting a receptive score/ adhesive factors of the endometrium 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT02398630 - "Magnetic Resonance Imaging Hysterosalpingography for the Integral Evaluation of the Infertile Patient." N/A
Completed NCT03055442 - Myo-inositol/D-chiro-inositol Ratio in Follicular Fluid N/A
Completed NCT03023514 - Lipoic Acid Supplementation in IVF Phase 4